Status:
RECRUITING
Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy
Lead Sponsor:
Peking University Cancer Hospital & Institute
Collaborating Sponsors:
The Affiliated Hospital of Qingdao University
North Sichuan Medical College
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with neoadjuvant therapy
Eligibility Criteria
Inclusion
- Aged ≥18 years old; ECOG 0 or 1;
- Patients with newly diagnosis HER2 positive or suspicious positive tumors;
- Receives neoadjuvant therapy
- Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions;
- Life expectancy \> 3 months -
Exclusion
- Significant hepatic or renal dysfunction;
- Is pregnant or ready to pregnant;
- Cannot keep their states for half an hour;
- Refused to join the clinical research;
- Suffering from claustrophobia or other mental disorders;
- Any other situation that researchers considered it unsuitable to participate in the trial.
Key Trial Info
Start Date :
January 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06909604
Start Date
January 1 2025
End Date
December 30 2026
Last Update
April 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Cancer Hospital & Institute
Beijing, China, 100142